| Name | Title | Contact Details |
|---|
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
Boehringer Ingelheim Pharma Inc. is a Ridgefield, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cansortium Holdings utilizes a unique combination of capital and expertise in making strategic investments to help launch mature and professional cannabis markets. As global regulations evolve, Consortium Holdings is well-positioned to expand its presence in the U.S. and Puerto Rico.
Professional Gem Sciences Inc is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lumate Health is a Cognitive Behavioral Teletherapy Platform treating teenagers and young adults with anxiety-related mental health disorders.